Chemotherapy is recommended when cancer cells need to be destroyed, shrunk, or controlled using drugs that travel through your entire body. The decision depends on your cancer type, how far it has spread, your overall health, and increasingly, the biological features of the tumor itself. Sometimes the goal is a complete cure. Other times, chemotherapy is recommended to extend life or relieve symptoms caused by a growing tumor.
The Three Goals Behind a Recommendation
Not all chemotherapy is prescribed with the same intent, and understanding the goal changes what you can expect from treatment. Oncologists generally frame chemotherapy around three distinct purposes: curative, life-extending, and palliative.
Curative chemotherapy is given when there’s a high probability of eliminating the cancer entirely and preventing it from coming back. This applies to cancers with strong track records of responding to chemotherapy, including Hodgkin lymphoma, testicular cancer, and acute lymphocytic leukemia. It also covers situations where chemotherapy is used alongside surgery for localized breast cancer, colorectal cancer, or lung cancer to destroy any microscopic cancer cells that surgery alone might miss.
Life-extending chemotherapy is recommended when a cure isn’t realistic but the drugs can meaningfully add months or years to a person’s life. The primary intent here isn’t symptom relief. It’s buying time, sometimes for deeply personal reasons like reaching a milestone or being present for a family event.
Palliative chemotherapy focuses on comfort rather than survival. When a tumor is pressing on nerves, blocking an organ, or causing pain, chemotherapy (or radiation) can shrink it enough to relieve those symptoms. The American Society of Clinical Oncology recommends that all patients with advanced cancer receive palliative care, and chemotherapy can be part of that plan when it improves quality of life. Studies have shown that integrating palliative care early after an advanced cancer diagnosis can improve mood, quality of life, and in some cases even survival.
Before Surgery vs. After Surgery
When chemotherapy is paired with surgery, the timing matters and depends on the clinical situation.
Chemotherapy given before surgery is called neoadjuvant therapy. It’s recommended when a tumor is too large to remove safely, when the surgeon wants to shrink it first, or when preserving the organ is a priority. In breast cancer, for example, neoadjuvant chemotherapy is used for locally advanced tumors, cases with lymph node involvement, large masses, or when a patient wants to keep as much breast tissue as possible. It can also be recommended when a surgeon determines that operating on a large mass could be risky due to attachment to underlying tissue or bleeding concerns. Neoadjuvant treatment increases the chances of a less extensive surgery, though it doesn’t always improve overall survival compared to operating first.
Chemotherapy given after surgery is called adjuvant therapy. Its purpose is straightforward: reduce the risk of the cancer coming back by eliminating any remaining cancer cells that imaging can’t detect. This is one of the most common reasons chemotherapy is recommended for early-stage solid tumors like breast, colon, and lung cancers.
How Tumor Biology Shapes the Decision
Modern oncology increasingly relies on the genetic and molecular profile of a tumor, not just its size or stage, to decide whether chemotherapy is worth the side effects. This shift means two people with the same cancer type and stage might get very different recommendations.
In hormone-receptor-positive breast cancer, a genomic test called Oncotype DX assigns a recurrence score that directly influences treatment. Scores under 10 indicate low risk, scores between 11 and 25 are intermediate, and scores of 26 or above are high risk. Most patients with low and intermediate scores are treated with hormone therapy alone after surgery. Those with high scores are recommended chemotherapy in addition to hormone therapy because their cancer is more likely to return without it.
Similar molecular testing exists for other cancers. In non-small cell lung cancer, for instance, tumors are tested for specific protein levels and genetic mutations that determine whether immunotherapy alone, chemotherapy alone, or a combination of both is the best first option. The presence or absence of certain markers can completely shift the treatment plan away from traditional chemotherapy.
Your Physical Health Plays a Role
Even when a cancer would typically call for chemotherapy, your body has to be strong enough to tolerate it. Oncologists assess this using a performance status scale that rates how well you can carry out daily activities. The scale runs from 0 (fully active with no restrictions) to 4 (completely bedridden).
Most clinical trials that establish chemotherapy’s effectiveness enroll patients who are fully active or only mildly limited, corresponding to scores of 0 or 1. Fewer than 5% of patients in the trials that led to FDA drug approvals had scores of 2 or higher. In everyday practice, though, chemotherapy is commonly recommended for patients with solid tumors who score 0, 1, or 2, meaning they’re up and about for at least half the day even if they can’t do physically demanding work.
Beyond activity level, your organ function matters. Before starting treatment, blood tests check how well your liver and kidneys are working, since these organs process and clear the drugs from your body. If kidney or liver function is significantly impaired, your oncologist may adjust the treatment plan, switch to a different drug, lower the dose, or in some cases decide that chemotherapy’s risks outweigh its benefits.
How the Recommendation Gets Made
A chemotherapy recommendation rarely comes from a single doctor. Most cancer centers use a multidisciplinary tumor board, a regular meeting where specialists review individual cases together. The team typically includes a surgeon, medical oncologist, radiation oncologist, pathologist, and radiologist. Depending on the cancer type, genetics specialists, nuclear medicine doctors, palliative care social workers, and patient coordinators may also participate.
The process usually starts with the surgeon or referring doctor presenting your case. The radiologist walks through your imaging, the pathologist explains the biopsy findings, and then the group discusses specific treatment questions. Should surgery come first, or should chemotherapy shrink the tumor beforehand? Is radiation a better option? Does the molecular profile suggest immunotherapy instead? The group works through these questions using evidence-based guidelines and arrives at a consensus recommendation. This collaborative approach is designed to ensure no single perspective dominates and that the treatment plan reflects the best available evidence for your specific situation.
When Chemotherapy Is Not Recommended
There are situations where chemotherapy is skipped even when the cancer itself would normally respond to it. Poor organ function, particularly kidney failure, is one of the more common reasons. Patients who are elderly with significant frailty may also be steered toward gentler alternatives, as compliance with full chemotherapy regimens drops substantially in older patients compared to those with isolated organ problems.
Some cancers simply don’t respond well enough to chemotherapy to justify the side effects. Certain slow-growing cancers are better managed with hormone therapy, targeted drugs, or active surveillance. And in cases where the cancer is very advanced and a patient’s functional status is severely limited, the toxicity of chemotherapy can reduce quality of life without extending it, making supportive care the better path.
When a standard drug is contraindicated due to a specific organ problem, oncologists often have alternatives. A patient whose kidneys can’t handle one drug may tolerate a substitute, though the effectiveness of the backup option isn’t always as well established. These tradeoffs are part of why the decision is so individualized.
Chemotherapy Combined With Newer Treatments
Chemotherapy is increasingly given alongside immunotherapy rather than as a standalone treatment. In many advanced cancers, particularly lung cancer, the combination of chemotherapy with immune checkpoint drugs has become the standard first-line approach. Immunotherapy works by helping your immune system recognize and attack cancer cells, while chemotherapy kills rapidly dividing cells directly. Together, they can be more effective than either alone.
For some patients whose tumors have very high levels of certain immune markers, immunotherapy alone may be sufficient, and chemotherapy can be avoided entirely. This is another reason molecular testing has become so central to treatment planning. The question is no longer just “should you get chemotherapy?” but “what combination of treatments gives you the best outcome with the fewest side effects?”